Literature DB >> 11806663

Surveillance of antibiotic resistance in Neisseria gonorrhoeae in the WHO Western Pacific Region, 2000.

.   

Abstract

A long-term program of surveillance of antimicrobial resistance in Neisseria gonorrhoeae isolated in the World Health Organization's Western Pacific Region (WHO WPR GASP) continued in 2000. About 11,000 gonococci were examined in 15 focal points. Widespread resistance to the penicillin group of antibiotics was confirmed. Resistance to quinolone antibiotics, already widely dispersed, increased further with a shift to higher levels of resistance in many centres. Gonococci with decreased susceptibility to third generation cephalosporins were observed in 5 centres. Spectinomycin resistance was infrequently encountered. Options for cheap and effective treatment of gonorrhoea in the WPR are increasingly limited.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11806663

Source DB:  PubMed          Journal:  Commun Dis Intell Q Rep        ISSN: 1447-4514


  4 in total

1.  Antimicrobial susceptibility of Neisseria gonorrhoeae strains isolated in Guangzhou, China, 1996-2001.

Authors:  H P Zheng; W L Cao; X Z Wu; L G Yang
Journal:  Sex Transm Infect       Date:  2003-10       Impact factor: 3.519

Review 2.  The Prevalence of Antimicrobial Resistant Neisseria gonorrhoeae in Papua New Guinea: A Systematic Review and Meta-Analysis.

Authors:  Barne Willie; Emma L Sweeney; Steven G Badman; Mark Chatfield; Andrew J Vallely; Angela Kelly-Hanku; David M Whiley
Journal:  Int J Environ Res Public Health       Date:  2022-01-28       Impact factor: 3.390

3.  International travel and sexually transmitted disease.

Authors:  Paul Etkind; Sylvie Ratelle; Harvey George
Journal:  Emerg Infect Dis       Date:  2003-12       Impact factor: 6.883

4.  Antimicrobial resistance in Neisseria gonorrhoeae in China: a meta-analysis.

Authors:  Yawen Chen; Yanhong Gong; Tingting Yang; Xingyue Song; Jing Li; Yong Gan; Xiaoxv Yin; Zuxun Lu
Journal:  BMC Infect Dis       Date:  2016-03-03       Impact factor: 3.090

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.